The Escherichia coli expression system is routinely used in the production of proteins that require no eukaryotic post-translational modifications. As an expression system, E. coli cultures are well-established, with time-tested growth and optimal performance in the production of antigens.
Our E.co-Vacc Technology is a synergystic tool in the production of recombinant proteins as vaccine components that can also be combined with the OMV-Vacc or Con-Vacc platforms to develop novel and effective vaccine candidates.
Speed: A fast, cost-effective, and versatile production platform.
Reliability: Robust and high-productivity expression of recombinant proteins.
Access: A universally used antigen production system.
Relevant: Applied to protein expression for vaccines against cancer and infectious diseases.
We are working with Cimcure to develop a unique cancer vaccine that targets blood vessels supplying solid cancers and thus prevents tumor growth. Building on our E.co-Vacc technology, the vaccine candidate inhibits angiogenesis by eliciting an immune response against extracellular vimentin secreted by tumor endothelial cells.
Learn more about the innovative work we are doing with E.co-Vacc.